Bremelanotide news from FierceBiotech
NewsPalatin slashes staff, dumps research program
Palatin Technologies is cutting about a third of its workforce and dumping one of its lead development programs--an effort to find a better tolerated successor to sildenafil. After studying research Read more...
Palatin slashes staff following FDA objections
With its lead therapy raising some serious safety concerns at the FDA, Palatin Technologies Read more...
King bails on Palatin's FSM program
Less than two weeks after U.S. drug regulators raised serious doubts about the safety of bremelanotide for ED, King Read more...
| Press ReleasesPRESS RELEASE: Palatin Technologies Announces Reacquisition of Full Rights to Bremelanotide Program Palatin Technologies Announces Reacquisition of Full Rights to Bremelanotide Program CRANBURY, N.J. – September 10, 2007--Palatin Technologies today announced it has reacquired full rights to Read more... |
Paid Research Reports
- Leading Drug Delivery Companies and Technologies: Competitive landscape, company profiles and technological developments
- Drug Repositioning Strategies - Serendipity by design
- eHealthInsight Series: Online Patient Recruitment Strategies - Optimizing the clinical trial process
- Pricing & Reimbursement - Seven Major Markets Update
- Innovative Clinical Trial Design and Management: Trends, success stories and impact upon R&D budgets